Share this video  

ASCO 2022 | FOLFIRINOX, gemcitabine + paclitaxel to enhance surgery outcomes for locally advanced PC

Combined chemotherapy with FOLFIRINOX, gemcitabine and paclitaxel has previously been demonstrated to improve overall-survival (OS) in metastatic pancreatic cancer. Rainer Fietkau, MD, PhD, University Hospital Erlangen, Erlangen, Germany discusses utilizing this chemotherapy regimen to help avoid the development of distant metastases in patients with locally advanced disease during induction chemotherapy to enhance the benefit of surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.